Morgan Stanley Is Bullish on PTC Therapeutics, Inc. (PTCT) as Small-Cap Biotech Outlook Improves

We recently compiled a list of the 15 High Growth Mid-Cap Stocks to Buy. PTC Therapeutics, Inc. is among the best high growth stocks.

TheFly reported on January 8 that Morgan Stanley raised its price target on PTCT to $90 from $78 and reiterated an Overweight rating. The analyst stated that while large-cap biopharma faces increasing pressure from impending patent expirations, the firm anticipates that U.S. small- to mid-cap biotechnology stocks will continue to outperform in 2026 as more commercial-stage companies generate sustainable cash flows.

Separately, PTC Therapeutics, Inc. (NASDAQ:PTCT) reported on January 12 that for full-year 2026, it expects total product revenue in the range of $700 million to $800 million, excluding Evrysdi royalty income and collaboration-related revenue. The business also projects GAAP R&D and SG&A expenses of $775 million to $815 million, while non-GAAP R&D and SG&A expenses are forecast between $680 million and $720 million, excluding approximately $95 million in non-cash stock-based compensation.

PTC Therapeutics, Inc. (NASDAQ:PTCT) is a global biopharmaceutical company that discovers, develops, and commercializes innovative medicines for rare genetic disorders. It focuses on transformational therapies, including small molecules and gene therapies, to improve health outcomes for patients with serious unmet needs worldwide.

While we acknowledge the potential of PTCT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 12 Best Multibagger Stocks to Buy Heading into 2026 and 7 Best Rising Tech Stocks to Buy Now.

Disclosure: None.